CytoMed Therapeutics (GDTC) said Monday it has signed a five-year business and research collaboration deal with SunAct Cancer Institute.
The companies plan to explore the efficacy, potency, safety, and tolerability of CytoMed's proprietary allogeneic gamma delta T cells to treat different cancers in human subjects through clinical research, CytoMed said.
The joint effort will include a phase 2 investigator-initiated trial in India that will be jointly sponsored by the two companies, CytoMed said.
CytoMed shares were up over 22% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.